Funding news · Sep 22, 2026
UltraSight Raises $24M Series C+ Led by ALIVE HealthTech Fund
UltraSight Raises $24M Series C+
UltraSight, an Israeli medical technology company, has raised a $24 million Series C+ round led by ALIVE HealthTech Fund. The round was announced on September 22, 2026.
What the Company Does
UltraSight develops the Echosystem, an AI-guided platform that enables trained medical staff — not only specialist sonographers — to perform diagnostic-quality cardiac ultrasound at the point of care.
The company has received FDA clearance for its real-time AI guidance software and collaborates with Mayo Clinic on next-generation cardiac care. Its Echosystem is installed in intensive care units at more than 10 medical facilities.
Round Details
| Item | Detail |
|---|---|
| Round type | Series C+ |
| Amount | $24 million |
| Currency | USD |
| Date | September 22, 2026 |
| Lead investor | ALIVE HealthTech Fund |
Participating Investors
- ALIVE HealthTech Fund (lead)
- NYU Innovation Venture Fund
- Deep Insight
- Mayo Clinic
- Iron Nation
- Connecticut Innovations
- Star51 Capital
- eHealth Ventures
Company Background
UltraSight was founded in 2018 and is based in Rehovot, Israel. The company's focus is on widening access to cardiac ultrasound by moving image acquisition toward non-specialist staff at the point of care, with AI providing real-time guidance during the exam.
Why It Matters
Cardiac ultrasound has traditionally depended on specialist sonographers, a constraint that limits where and how quickly diagnostic imaging can be performed. UltraSight's approach targets that bottleneck directly: the Echosystem is designed so that trained medical staff can capture diagnostic-quality images, with AI guidance supporting them in real time.
The presence of Mayo Clinic among the investors follows the company's stated collaboration with the clinic on next-generation cardiac care. The Echosystem's installation in intensive care units at more than 10 medical facilities indicates early deployment in a setting where timely cardiac assessment is critical.
At a Glance
- Company: UltraSight
- Headquarters: Rehovot, Israel
- Founded: 2018
- Product: Echosystem AI-guided cardiac ultrasound platform
- Regulatory status: FDA clearance for real-time AI guidance software
- Deployment: Installed in ICUs at more than 10 medical facilities
- Collaboration: Mayo Clinic
- Round: Series C+
- Amount raised: $24 million
- Lead investor: ALIVE HealthTech Fund
- Announced: September 22, 2026